JBJS Open Access (Dec 2019)

Total Hip Arthroplasty in a Low-Income Country

  • Simon Matthew Graham, MBChB, MRCS, MSc(Res), FRCS,
  • Nicholas Howard, MBChB, MRCS, MSc, FRCS,
  • Chipiliro Moffat,
  • Nicholas Lubega, MBChB, MMed(Ortho), FCS(ECSA), MBA,
  • Nyengo Mkandawire, BMBS, FRCS, MCh(Orth), FCS(ECSA),
  • William J. Harrison, MA(Oxon), FRCS(Tr&Orth)

DOI
https://doi.org/10.2106/JBJS.OA.19.00027
Journal volume & issue
Vol. 4, no. 4
p. e0027

Abstract

Read online

Background:. We describe our 10-year experience performing total hip arthroplasty (THA) in patients enrolled in the National Joint Registry of the Malawi Orthopaedic Association. Methods:. Eighty-three THAs were performed in 70 patients (40 male and 30 female) with a mean age of 52 years (range, 18 to 77 years). The cohort included 24 patients (14 male and 10 female; mean age, 52 years [range, 35 to 78 years]) who were human immunodeficiency virus (HIV)-positive. Results:. The main indications for surgery were osteonecrosis (n = 41 hips) and osteoarthritis (n = 26 hips). There were no deaths perioperatively and no early complications at 6 weeks. Forty-six patients (59 THAs) were seen at 10 years postoperatively, with a mean Harris hip score (HHS) of 88 (range, 41 to 91) and a mean Oxford Hip Score (OHS) of 46 (range, 25 to 48). Five hips (8% of 59) were revised due to loosening (n = 4) and fracture (n = 1). There were no infections or dislocations. Fourteen patients died, including 4 HIV-positive patients, of unknown causes in the follow-up period, and 10 patients were lost to follow-up. In the group of 24 HIV-positive patients, there were no early complications, and the mean HHS was 88 (range, 76 to 91) at >10 years. Conclusions:. Our 10-year experience and long-term outcomes after primary THA in a low-income setting show that good results can be achieved within a controlled hospital environment, thereby establishing a benchmark against which other hospitals and registries in similar low-income countries can compare their results. Level of Evidence:. Therapeutic Level IV. See Instructions for Authors for a complete description of levels of evidence.